GSK press releases
Follow
ViiV Healthcare’s long-acting Cabenuva (cabotegravir + rilpivirine) for HIV demonstrates superior efficacy compared to daily oral therapy for people with adherence challenges; results published in NEJM
Final data from LATITUDE study show switch to long-acting injectable treatment reduced the risk of virological failure by nearly half.
